People with fever, pregnant and breastfeeding women avoid Covaxin: Bharat Biotech

Bharat Biotech said in an ongoing clinical trial Covaxin has been shown to generate immunity following two doses given four weeks apart.

Published: 19th January 2021 12:54 PM  |   Last Updated: 19th January 2021 03:02 PM   |  A+A-

Covid Vaccine

The Centre has procured 55 lakh doses of Covaxin from Bharat Biotech to inoculate healthcare workers. (File Photo | Vinay Madapu, EPS)

By PTI

HYDERABAD: Bharat Biotech's fact sheet on COVID-19 vaccine Covaxin, has advised pregnant or breastfeeding women, besides people with high fever or bleeding disorders, not to take the antidote.

The vaccine maker in the fact sheet on Covaxin, posted in its website, said the clinical efficacy of the vaccine is yet to be established and is being studied in Phase 3 clinical trial and hence it is important to appreciate that receiving the vaccine does not mean other precautions related to COVID- 19 need not be followed.

"You should not get Bharat Biotech's COVID-19 vaccine Covaxin if you have any history of allergies. Have high fever. Have bleeding disorder or are a blood thinner. Immune compromised or are a medicine that affects your immune system. Are pregnant. Are breastfeeding. Have received another COVID-19 vaccine. Any other serious health related issues, as determined by the vaccinator/ Officer supervising vaccination," the fact sheet said.

ALSO READ: Centre issues Letter of Comfort to Bharat Biotech for 45 lakh doses of Covaxin

The fact sheet also asked people to inform the vaccinator or a supervising official about their medical condition before taking the vaccine.

Bharat Biotech said in an ongoing clinical trial Covaxin has been shown to generate immunity following two doses given four weeks apart.

Covaxin is a vaccine with approval for restricted use in emergency situations that may prevent COVID-19.

ALSO READ: India records 10,064 new COVID-19 cases, deaths lowest in eight months

The Central Licensing Authority has granted permission for the sale or distribution of the antidote for restricted use in emergency situations in public interest as an abundant precaution, in clinical trial mode, the fact sheet said.

Covaxin is a highly purified and inactivated two-dose SARS-CoV-2 vaccine, manufactured in a Vero cell manufacturing platform with an excellent safety track record of more than 300 million doses, the company had said.

Covaxin is India's totally indigenous COVID-19 vaccine developed in collaboration with the Indian Council of Medical Research and National Institute of Virology.

ALSO READ: Pandemic response probe team says WHO, China could have acted faster

The inactivated vaccine is developed and manufactured in Bharat Biotech's BSL-3 (Bio-Safety Level 3) biocontainment facility, one of its kind in the world.

Stay up to date on all the latest Nation news with The New Indian Express App. Download now

Comments

Disclaimer : We respect your thoughts and views! But we need to be judicious while moderating your comments. All the comments will be moderated by the newindianexpress.com editorial. Abstain from posting comments that are obscene, defamatory or inflammatory, and do not indulge in personal attacks. Try to avoid outside hyperlinks inside the comment. Help us delete comments that do not follow these guidelines.

The views expressed in comments published on newindianexpress.com are those of the comment writers alone. They do not represent the views or opinions of newindianexpress.com or its staff, nor do they represent the views or opinions of The New Indian Express Group, or any entity of, or affiliated with, The New Indian Express Group. newindianexpress.com reserves the right to take any or all comments down at any time.

flipboard facebook twitter whatsapp